Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
Open accessThe DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Resistance to chemotherapy is a major obstacle to the effective treatment of many tumor types. Although many anticancer therapies can alter tumor growth, in most cases the effect is not long lasting. Consequently, there is a significant need for new agents with low susceptibility to common drug resistance mechanisms in order to improve response rates and potentially extend survival. Approximately 30% of the women diagnosed with early-stage disease in turn progress to metastatic breast cancer, for which therapeutic options are limited. Current recommendations for first-line chemotherapy include anthracycline-based regimens and taxanes (paclitaxel and docetaxel). They typically give response rates of 30 to 70% but the responses are often not durable, with a time to progression of 6 to 10 months. Patients with progression or resistance may be administered capecitabine, gemcitabine, vinorelbine, albumin-bound paclitaxel, or ixabepilone, while other drugs are being evaluated. Response rates in this setting tend to be low (20 to 30%); the median duration of responses is <6 months and the results do not always translate into improved long-term outcomes. The present article reviews treatment options in taxane-resistant metastatic breast cancer and the role of ixabepilone in this setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Th e HER2-specifi c inhibitors trastuzumab and lapatinib have demonstrated effi cacy in the metastatic setting [15-17].”
BackgroundTumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 1×
“Tumor stem cells have been identifi ed in many malignancies, including breast cancer [19,20].”
BackgroundLapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153 · cited 1×
“Patients with progression or resistance may be adminis tered capecitabine, gemcitabine, vinorelbine, or albumin-bound paclitaxel, with capecitabine being the only one approved by the US Food and Drug Administration (FDA) after anthracyclines and taxanes [4,5].”
BackgroundA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672 · cited 1×
“Glutathione and glutathione S-transferase are involved in the detoxifi cation of alkylating agents and cisplatin, so the modulation of their activity might aff ect the resistance to these compounds [68].”
BackgroundMiwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240 · cited 1×
“Capecitabine is hydrolyzed in the liver by the enzyme carboxylesterase to produce 5 ́-deoxy-5-fl uorocytidine, is then deaminated on its pyrimidine ring to produce 5 ́-deoxy-5-fl uorouridine by the enzyme cytidine deaminase, located mainly in hepatic and neoplastic tissue, and fi nally thymidine phosphorylase produces…”
BackgroundLamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
Austin Doyle, L., & Ross, D. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206938 · Cited by 1,051
Triple-negative breast cancer: therapeutic options
Cleator, S., Heller, W., & Coombes, R. C. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70074-8 · Cited by 882 · cited 2×
“Four of the 15 responses occurred in patients with estrogen receptor-negative, progesterone receptor-negative, and HER2-negative (triple-negative) breast cancer, suggesting such a regimen may be eff ective for patients with this treatment-resistant subtype [91].”
BackgroundO'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867
Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer
Blum, J. L., Jones, S. E., Buzdar, A. U., LoRusso, P. M., Kuter, I., Vogel, C., Osterwalder, B., Burger, H.-U., Brown, C. S., & Griffin, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.485 · Cited by 783 · cited 2×
“Diarrhea (14%) and hand–foot syndrome (10%) were the only treatment-related adverse events that occurred with grade 3 or grade 4 intensity in more than 10% of patients [71].”
BackgroundMethodAas, T., Børresen, A.-L., Geisler, S., Smith-Sørensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., & Lønning, P. E. (1996) · Nature Medicine · doi:10.1038/nm0796-811 · Cited by 736
Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.
Bollag, D. M., McQueney, P. A., Zhu, J., Hensens, O. D., Koupal, L. R., Liesch, J. M., Goetz, M., Lazarides, E., & Woods, C. M. (1995) · PubMed · Cited by 685
Giannakakou, P., Sackett, D. L., Kang, Y.-K., Zhan, Z., Buters, J. T. M., Fojo, T., & Poruchynsky, M. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.27.17118 · Cited by 681
Extending Survival with Chemotherapy in Metastatic Breast Cancer
O'Shaughnessy, J. (2005) · The Oncologist · doi:10.1634/theoncologist.10-90003-20 · Cited by 668
GERTH, K., BEDORF, N., HÖFLE, G., IRSCHIK, H., & REICHENBACH, H. (1996) · The Journal of Antibiotics · doi:10.7164/antibiotics.49.560 · Cited by 631 · cited 1×
“Epothilones A and B, which are two major fermentation products originally isolated from the broth of the myxobacterium Sorangium cellulosum, were found to stabilize polymerized microtubules and therefore to inhibit depolymerization [72,73].”
BackgroundDumontet, C., & Sikic, B. I. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.1061 · Cited by 574
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W. J., Pritchard, K. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.027 · Cited by 547 · cited 1×
“Th e frequency and severity of this toxicity with ixabepilone was comparable with that observed with other microtubule inhibitors (2 to 32%) [96-99].”
ResultLee, F. Y., Borzilleri, R. M., Fairchild, C. R., Kim, S., Long, B. H., Raventós-Suárez, C., Vite, G. D., Rose, W. C., & Kramer, R. A. (2001) · PubMed · Cited by 490
Thomas, E. S., Gomez, H. L., Li, R. K., Chung, H.-C., Fein, L. E., Chan, V. F., Jassem, J., Pivot, X. B., Klimovsky, J. V., de Mendoza, F. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6557 · Cited by 481 · cited 3×
“3% [92] to anthracyclines and received ≥1 prior regimen for MBC; 85% had resistant to taxanesd progressed on prior taxane therapy for Median DOR 6.”
BackgroundSelf-citationGiannakakou, P., Gussio, R., Nogales, E., Downing, K. H., Zaharevitz, D., Bollbuck, B., Poy, G., Sackett, D., Nicolaou, K. C., & Fojo, T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040546297 · Cited by 477 · cited 4×
“In addition, ixabepilone is active in preclinical tumor models that are resistant to paclitaxel due to mutations in β-tubulin [22,43].”
BackgroundInfluentialPeripheral Neuropathy Induced by Microtubule-Stabilizing Agents
Lee, J. J., & Swain, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0543 · Cited by 472 · cited 1×
“Th e frequency and severity of this toxicity with ixabepilone was comparable with that observed with other microtubule inhibitors (2 to 32%) [96-99].”
ResultTargeting Microtubules for Cancer Chemotherapy
Zhou, J., & Giannakakou, P. (2005) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011053352569 · Cited by 468 · cited 2×
“Binding disrupts the microtubule dynamics by stabilizing microtubules and inducing microtubule bundles, thereby inhibiting cell division and triggering apoptosis [38].”
BackgroundABC Transporters as Phenotypic Markers and Functional Regulators of Stem Cells
Bunting, K. D. (2002) · STEM CELLS · doi:10.1002/stem.200011 · Cited by 458
Trock, B. J., Leonessa, F., & Clarke, R. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.13.917 · Cited by 434 · cited 2×
“Th is increased P-gp expression was associated with a threefold increased risk of failure to respond to chemotherapy [26].”
BackgroundHER2 therapy: Molecular mechanisms of trastuzumab resistance
Nahta, R., & Esteva, F. J. (2006) · Breast Cancer Research · doi:10.1186/bcr1612 · Cited by 433
Thomas, E. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5019 · Cited by 428
The Binding Mode of Epothilone A on α,ß-Tubulin by Electron Crystallography
Nettles, J. H., Li, H., Cornett, B., Krahn, J. M., Snyder, J. P., & Downing, K. H. (2004) · Science · doi:10.1126/science.1099190 · Cited by 421 · cited 3×
“Low susceptibility to multiple mechanisms of drug resistance [23,76]”
BackgroundMicrotubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer
Rouzier, R., Rajan, R., Wagner, P., Hess, K. R., Gold, D. L., Stec, J., Ayers, M., Ross, J. S., Zhang, P., Buchholz, T. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408974102 · Cited by 413 · cited 3×
“Changes in microtubule-associated proteins, such as microtubule-associated protein-4 and tau, can also aff ect the microtubule dynamics and modulate sensitivity to taxanes and vincas [46,47].”
BackgroundBlum, J. L., Dieras, V., Lo Russo, P. M., Horton, J., Rutman, O., Buzdar, A., & Osterwalder, B. (2001) · Cancer · doi:10.1002/1097-0142(20011001)92:7<1759::aid-cncr1691>3.0.co;2-a · Cited by 398 · cited 2×
“With regard to the safety, treatment was well tolerated and the only grade 3 treatment-related adverse events reported in ≥10% of patients were hand–foot syndrome (22%), diarrhea (16%), and stomatitis (12%) [8].”
BackgroundPerez, E. A., Lerzo, G., Pivot, X., Thomas, E., Vahdat, L., Bosserman, L., Viens, P., Cai, C., Mullaney, B., Peck, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3849 · Cited by 393
Structure of tubulin at 6.5 Å and location of the taxol-binding site
Nogales, E., Grayer Wolf, S., Khan, I. A., Ludueña, R. F., & Downing, K. H. (1995) · Nature · doi:10.1038/375424a0 · Cited by 389
Nabholtz, J. M., Gelmon, K., Bontenbal, M., Spielmann, M., Catimel, G., Conte, P., Klaassen, U., Namer, M., Bonneterre, J., Fumoleau, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1858 · Cited by 380 · cited 1×
“Th e frequency and severity of this toxicity with ixabepilone was comparable with that observed with other microtubule inhibitors (2 to 32%) [96-99].”
ResultBernicker, E. H. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540150066034 · Cited by 354
Burger, H., Foekens, J. A., Look, M. P., Gelder, M. E. M., Klijn, J. G. M., Wiemer, E. A. C., Stoter, G., & Nooter, K. (2003) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 341
Mozzetti, S., Ferlini, C., Concolino, P., Filippetti, F., Raspaglio, G., Prislei, S., Gallo, D., Martinelli, E., Ranelletti, F. O., Ferrandina, G., et al. (2005) · PubMed · Cited by 323
Mozzetti, S., Ferlini, C., Concolino, P., Filippetti, F., Raspaglio, G., Prislei, S., Gallo, D., Martinelli, E., Ranelletti, F. O., Ferrandina, G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.298.11.1 · Cited by 303
Thomas, E., Tabernero, J., Fornier, M., Conté, P., Fumoleau, P., Lluch, A., Vahdat, L. T., Bunnell, C. A., Burris, H. A., Viens, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9102 · Cited by 290 · cited 3×
“An international, multicenter phase II trial evaluated single-agent ixabepilone in patients with MBC who were previously treated with an anthracycline-based regimen and were resistant to a taxane [88].”
BackgroundMethodSelf-citationWiner, E. P., Berry, D. A., Woolf, S., Duggan, D., Kornblith, A., Harris, L. N., Michaelson, R. A., Kirshner, J. A., Fleming, G. F., Perry, M. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.048 · Cited by 270
ATP binding cassette transporters and drug resistance in breast cancer.
Leonessa, F., & Clarke, R. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100043 · Cited by 259 · cited 3×
“As determined by RT-PCR, MRP1 is expressed in nearly all breast cancers (and in approximately one-half of normal breast tissues) [25].”
BackgroundInfluentialKamath, K., Wilson, L., Cabral, F., & Jordan, M. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414477200 · Cited by 247 · cited 3×
“Altered expression of β-tubulin isotypes [41,42]”
BackgroundReichardt, P., von Minckwitz, G., Thuss-Patience, P. C., Jonat, W., Kölbl, H., Jänicke, F., Kieback, D. G., Kuhn, W., Schindler, A. E., Mohrmann, S., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg346 · Cited by 237
Breast cancer resistance protein (BCRP/ABCG2)
Staud, F., & Pavek, P. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.11.004 · Cited by 232
Kavallaris, M., Tait, A., Walsh, B. J., He, L., Horwitz, S. B., Norris, M. D., & Haber, M. (2001) · PubMed · Cited by 221
Sládek, N. E., Kollander, R., Sreerama, L., & Kiang, D. T. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-001-0412-4 · Cited by 212 · cited 1×
“Higher levels of ALDH3A1 have been found in breast cancer cells compared with normal tissues [67].”
BackgroundAltmann, K.-H., Wartmann, M., & O’Reilly, T. (2000) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(00)00009-3 · Cited by 191 · cited 7×
“Low susceptibility to multiple mechanisms of drug resistance [23,76]”
BackgroundInfluentialThe Biology and Medicinal Chemistry of Epothilones
Wartmann, M., & Altmann, K. (2012) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011023354489 · Cited by 182 · cited 1×
“Ixabepilone has low susceptibility to various drug resistance mechanisms, such as MDR overexpression [81], β-tubulin mutations [82], and the overexpression of the βIII-tubulin isotype [22,77,83].”
BackgroundBlum, J. L., Savin, M. A., Edelman, G., Pippen, J. E., Robert, N. J., Geister, B. V., Kirby, R. L., Clawson, A., & O'Shaughnessy, J. A. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.n.049 · Cited by 172
Breast Cancer — Loss of PTEN Predicts Resistance to Treatment
Pandolfi, P. P. (2004) · New England Journal of Medicine · doi:10.1056/nejmcibr043143 · Cited by 167 · cited 1×
“Th e tumor suppressors phosphatase and tensin homolog deleted on chromosome 10 and p27 both regulate apoptosis, and the decreased expression of these proteins has been proposed to aff ect the response to trastuzumab [65] and resistance to chemotherapy [66], respectively.”
BackgroundZhang, C. C., Yang, J.-M., White, E., Murphy, M., Levine, A., & Hait, W. N. (1998) · Oncogene · doi:10.1038/sj.onc.1201658 · Cited by 159 · cited 3×
“Changes in microtubule-associated proteins, such as microtubule-associated protein-4 and tau, can also aff ect the microtubule dynamics and modulate sensitivity to taxanes and vincas [46,47].”
BackgroundDo β-tubulin mutations have a role in resistance to chemotherapy?
Berrieman, H. K., Lind, M., & Cawkwell, L. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01411-1 · Cited by 153
O’Donovan, N., Crown, J. P., Stunell, H., Hill, A. D. K., McDermott, E. W. M., O’Higgins, N. J., & Duffy, M. J. (2003) · PubMed · Cited by 145
Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β‐tubulins
Tommasi, S., Mangia, A., Lacalamita, R., Bellizzi, A., Fedele, V., Chiriatti, A., Thomssen, C., Kendzierski, N., Latorre, A. C., Lorusso, V., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22557 · Cited by 145 · cited 1×
“In breast cancer patients who are treated with fi rst-line paclitaxel, high βIII-tubulin expression correlated with disease progression [51]; similar results were seen in paclitaxel-resistant ovarian cancer [52].”
ResultVinorelbine (Navelbine) as a salvage treatment for advanced breast cancer
Degardin, M., Bonneterre, J. M., Hecquet, B., Pion, J. M., Adeins, A., Horner, D., & Demaille, A. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058873 · Cited by 142 · cited 1×
“anthracycline-refractory and taxane-refractory disease range from 16 to 25%, and survival is limited [1,12-14].”
BackgroundHe, L., Yang, C. P., & Horwitz, S. B. (2001) · PubMed · Cited by 141
Targeting the Microtubules in Breast Cancer Beyond Taxanes: The Epothilones
Cortes, J., & Baselga, J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-3-271 · Cited by 137 · cited 2×
“Response rates range from 30% to 70% but the responses are often not durable, with a time to progression of 6 to 10 months [1,3].”
BackgroundVansteenkiste, J., Lara, P. N., Chevalier, T. L., Breton, J.-L., Bonomi, P., Sandler, A. B., Socinski, M. A., Delbaldo, C., McHenry, B. M., Lebwohl, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7097 · Cited by 132
Involvement of the DNA mismatch repair system in antineoplastic drug resistance
Lage, H., & Dietel, M. (1999) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050258 · Cited by 130 · cited 1×
“Th e loss of DNAmismatch repair activity – which mediates damage repair from many drugs including alkylating agents, platinum com pounds, and anthracyclines – has also been implicated in drug resistance [54].”
BackgroundBode, C. J., Gupta, M. L., Reiff, E. A., Suprenant, K. A., Georg, G. I., & Himes, R. H. (2002) · Biochemistry · doi:10.1021/bi0121611 · Cited by 127 · cited 1×
“Structural analyses indicate that epothilones may bind at or near the paclitaxel binding site on the β-tubulin protein [74-76].”
BackgroundMicrotubule Alterations and Mutations Induced by Desoxyepothilone B
Verrills, N. M., Flemming, C. L., Liu, M., Ivery, M. T. G., Cobon, G. S., Norris, M. D., Haber, M., & Kavallaris, M. (2003) · Chemistry & Biology · doi:10.1016/s1074-5521(03)00141-8 · Cited by 118 · cited 3×
“Altered expression of β-tubulin isotypes is found in many cancer cell lines and xenografts resistant to microtubule inhibitors, and this may be associated with the primary or acquired resistance to tubulin-binding agents observed clinically in many tumors (alterations in tubulin and associated proteins can aff ect the…”
BackgroundResistance to topoisomerase poisons due to loss of DNA mismatch repair
Fedier, A., Schwarz, V. A., Walt, H., Carpini, R. D., Haller, U., & Fink, D. A. (2001) · International Journal of Cancer · doi:10.1002/ijc.1356 · Cited by 117
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer
Bedard, P. L., Leo, A. D., & Piccart, M. J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.186 · Cited by 110 · cited 1×
“Polymorphisms in CYP3A4 and CYP2C8 associated with greater basal enzymatic activity lead to reduced plasma concentrations of the active drug [69].”
BackgroundMcDaid, H. M., Mani, S., Shen, H. J., Muggia, F. M., Sonnichsen, D. S., & Horwitz, S. B. (2002) · PubMed · Cited by 105
Filipits, M., Pohl, G., Rudas, M., Dietze, O., Lax, S., Grill, R., Pirker, R., Zielinski, C. C., Hausmaninger, H., Kubista, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.033 · Cited by 104 · cited 1×
“Some studies suggest that MRP1 expression correlates with poor survival in patients with early-stage disease who received chemo therapy, although a causal relationship is not clear [34].”
BackgroundLong, B. H., Wang, L., Lorico, A., Wang, R. C., Brattain, M. G., & Casazza, A. (1991) · PubMed · Cited by 102
Microtubule alterations and resistance to tubulin-binding agents (Review)
Drukman, S., & Kavallaris, M. (2002) · International Journal of Oncology · doi:10.3892/ijo.21.3.621 · Cited by 102 · cited 1×
“Altered expression of β-tubulin isotypes is found in many cancer cell lines and xenografts resistant to microtubule inhibitors, and this may be associated with the primary or acquired resistance to tubulin-binding agents observed clinically in many tumors (alterations in tubulin and associated proteins can aff ect the…”
BackgroundLarkin, A., O’Driscoll, L., Kennedy, S., Purcell, R. V., Moran, E., Crown, J. P., Parkinson, M. D., & CLYNES, M. M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20369 · Cited by 87
Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy
Rudas, M., Filipits, M., Taucher, S., Stranzl, T., Steger, G. G., Jakesz, R., Pirker, R., & Pohl, G. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1025751631115 · Cited by 82
Giaccone, G., & Pinedo, H. M. (1996) · The Oncologist · doi:10.1634/theoncologist.1-1-82 · Cited by 81
Végran, F., Boidot, R., Oudin, C., Riedinger, J., Bonnetain, F., & Lizard‐Nacol, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0725 · Cited by 76 · cited 1×
“Th e expression of a caspase-3s splice variant was also higher in breast carcinomas compared with nontumor tissue, and increased levels were correlated with resistance to cyclophosphamide-containing chemo therapy [60].”
BackgroundReduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells
Brown, I. M., Shalli, K., McDonald, S. L., Moir, S. E., Hutcheon, A. W., Heys, S. D., & Schofield, A. C. (2004) · Breast Cancer Research · doi:10.1186/bcr918 · Cited by 76
Whitehead, R. P., McCoy, S., Rivkin, S. E., Gross, H. M., Conrad, M. E., Doolittle, G. C., Wolff, R. A., Goodwin, J. W., Dakhil, S. R., & Abbruzzese, J. L. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-8440-x · Cited by 74 · cited 1×
“Ixabepilone has demonstrated clinical activity in some patients with tumors that are considered chemotherapy resistant, such as renal cell carcinoma [85] and advanced pancreatic cancer [86].”
BackgroundDevelopment of Novel Chemotherapeutic Agents to Evade the Mechanisms of Multidrug Resistance (MDR)
Lee, J. J., & Swain, S. M. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.09.013 · Cited by 68 · cited 3×
“Ixabepilone is not a good substrate for MDR and does not strongly induce P-gp expression (possibly because of the relatively fl exible structure of this compound), which may in part account for its activity in drug-resistant tumors [11].”
BackgroundAbility to Acquire Drug Resistance Arises Early during the Tumorigenesis Process
Yagüe, E., Arance, A. M., Kubitza, L., O’Hare, M. J., Jat, P., Ogilvie, C. M., Hart, I. R., Higgins, C. F., & Raguz, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2574 · Cited by 66 · cited 1×
“Accumulation of drug resistance mutations in stem cells, coupled with their highlevel expression of the ATP-binding cassette (ABC) drug transporters, noncycling state, and enhanced DNA repair, may contribute to the generation of resistance to chemotherapy [21].”
BackgroundBunnell, C. A., Vahdat, L. T., Schwartzberg, L. S., Gralow, J. R., Klimovsky, J., Poulart, V., Peck, R., & Thomas, E. S. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.n.026 · Cited by 62 · cited 3×
“In the phase II study, patients previously treated with anthracyclines and taxanes were treated with ixabepilone in addition to capecitabine [90].”
BackgroundWorse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF
Andersson, J., Larsson, L., Klaar, S., Holmberg, L., Nilsson, J., Inganäs, M., Carlsson, G. U., Öhd, J., Rudenstam, C.-M., Gustavsson, B. G., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi150 · Cited by 61
Moulder, S. L., Li, H., Wang, M., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0658-9 · Cited by 48 · cited 1×
“In a phase II trial, ixabepilone was combined with trastuzumab and carboplatin in patients with HER2positive MBC [94].”
BackgroundSchneider, J., Lucas, R., Sánchez, J., Ruibal, Á., Tejerina, A., & Martín, M. (2000) · PubMed · Cited by 47
Monotherapy options in the management of metastatic breast cancer
SEIDMAN, A. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70137-7 · Cited by 47 · cited 2×
“anthracycline-refractory and taxane-refractory disease range from 16 to 25%, and survival is limited [1,12-14].”
BackgroundBreast cancer, stem cells and prospects for therapy
Lynch, M., Cariati, M., & Purushotham, A. D. (2006) · Breast Cancer Research · doi:10.1186/bcr1513 · Cited by 43 · cited 2×
“Tumor stem cells have been identifi ed in many malignancies, including breast cancer [19,20].”
BackgroundPaclitaxel resistance in cells with reduced β-tubulin
Wang, Y., & Cabral, F. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.12.003 · Cited by 38
Efficacy and Safety of Ixabepilone, a Novel Epothilone Analogue
Pivot, X. B., Dufresne, A., & Villanueva, C. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.n.009 · Cited by 38 · cited 1×
“In vitro, ixabepilone inhibits the growth of several drug-resistant cell lines, including some that are resistant to paclitaxel (Table 3) [11,22,23,78-80].”
BackgroundMonotherapy options in the management of metastatic breast cancer
Seidman, A. D. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.37268 · Cited by 36
Kolman, A. (2005) · PubMed · Cited by 34
Shigeoka, Y. (2001) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hye082 · Cited by 27
Dumontet, C., Jaffrézou, J., Tsuchiya, E., Durán, G. E., Chen, K. G., Derry, W. B., Wilson, L., Jordan, M. A., & Sikic, B. I. (2004) · PubMed · Cited by 27
Lizard‐Nacol, S., Genne, P., Coudert, B. P., Riedinger, J., Arnal, M., Sancy, C., Brunet-Lecomte, P., & Fargeot, P. (1999) · PubMed · Cited by 25
Giaccone, G., & Pinedo, H. M. (1996) · PubMed · Cited by 24
Patterns of loss of heterozygosity in breast carcinoma during neoadjuvant chemotherapy
Oudin, C., Bonnetain, F., Boidot, R., Végran, F., Soubeyrand, M., Arnould, L., Riedinger, J., & Lizard‐Nacol, S. (2007) · International Journal of Oncology · doi:10.3892/ijo.30.5.1145 · Cited by 13
Cited by
Evaluation of the use of therapeutic peptides for cancer treatment
Marqus, S., Pirogova, E., & Piva, T. J. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0328-x · Cited by 512
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
Li, L., Yuan, L., Luo, J., Gao, J., Guo, J., & Xie, X. (2013) · Clinical and Experimental Medicine · doi:10.1007/s10238-012-0186-5 · Cited by 314
Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.
Murray, S., Briasoulis, E., Linardou, H., Bafaloukos, D., & Papadimitriou, C. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.02.011 · Cited by 261
Targeting autophagy during cancer therapy to improve clinical outcomes
Levy, J. M. M., & Thorburn, A. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.009 · Cited by 237
Metadata
- Authors
- Rivera, E., & Gomez, H.
- Venue
- Breast Cancer Research
- Published
- 2010-10
- Volume
- 12
- Issue
- S2
- Pages
- S2-S2
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2119349084
- Cited by
- 217
- References
- 90
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.